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CASE REPORT
ADENOCARCINOMA IN CAROLI’S DISEASE
TREATED BY LIVER TRANSPLANTATION
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M.T.VIDAL** and J. BONNIN,
Liver Transplantation Unit, Department of Surgery and Department of
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(Received 16 October 1992)
Caroli’s disease is characterized by congenital cystic dilatation of the intrahepatic bile ducts. In 7% of
casea a malignant tumor develops complicating the course of the disease.
We report the case of a 25 year-old woman in whom Caroli’s disease was diagnosed at the age of 11.
From that time on, she had several episodes of cholangitis. In 1989, the abdominal ultrasound and CT
scan showed dilatation of the intrahepatic bile ducts, intracystic lithiasis and a solid mass. FNA cytology
showed a papillary adenocarcinoma. At laparotomy a tumor was found occupying both hepatic lobes,
and intraoperative US showed another two nodules in the left lobe. The tumor was considered
unresectable. Examination of the hilar lymph nodes was tumor-negative. Two weeks later, the patient
underwent an ortothopic liver transplantation (OLT). The pathological examination confirmed Caroli’s
disease with adenocarcinoma. Two years after OLT, the patient is alive with normal liver function and
no evidence of disease.
To our knowledge this is the first case report of adenocarcinoma in Caroli’s disease treated by OLT.
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INTRODUCTION
In 1958, Caroli and Couinaud reported a congenital disease of the liver character-
ized by cystic dilatation of the intrahepatic bile ducts. Intracystic lithiasis, recurrent
cholangitis, and liver abscess are the most common complications associated with
Caroli’s disease. Less often, in 7% of cases, a malignant tumor develops, compli-
cating the course of the illness1’4’5’6’15.
We report a case of Caroli’s disease with an unresectable adenocarcinoma which
was treated with total hepatectomy and liver transplantation. To our knowledge,
this is the first case of liver transplantation for malignancy complicating Caroli’s
disease that has been described.
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CASE REPORT
A 25 year-old woman was diagnosed at laparotomy as having Caroli’s disease at the
age of 11. From that time on, she had several episodes of fever and upper
abdominal pain.
In August 1989, she suffered another episode of right upper quadrant pain,
radiating to the scapulor associated with fever and chills. An abdominal ultrasound
examination followed by a CT scan (Figure 1) showed dilatation of the intrahepatic
bile ducts, with intracystic lithiasis. A hyperechogenic solid mass filled some right
lobe cysts. Gallbladder lithiasis and a moderately dilated common bile duct were
also found. Fine needle aspiration cytology of the mass disclosed a papillary
adenocarcinoma.
The biochemistry parameters were: Hb 10.7 g/100 ml, WBC 12.900, PT 76%,
BUN 26 mg/100 ml, glucose 83 mg/100 ml, total bilirubin 0.4 mg/100 ml, AST 9
IU/1, ALT 12IU/I, AP 252 IU/1, total proteins 7.4 g/100 ml, albumin 3.9 g/100 ml,
and cholesterol 154 mg/100 ml. Blood cultures were negative.
A laparotomy performed to evaluate the feasibility of liver resection and to rule
out the possibility that the tumor had spread outside the liver. Mild dilatation of the
common bile duct, cholelithiasis, some lymphadenopathy at the porta hepatis, and
a mass in the right lobe, infiltrating the left hepatic lobe, were found. An
intraoperative ultrasonographic examination confirmed the presence of a tumor in
the right hepatic lobe, infiltrating segment IV. Two hyperechogenic nodules were
also discovered in segment III compatible with malignancy. Conventional hepatic
resection was not possible. There was no evidence extrahepatic spread of the tumor
and lymph node pathology was negative. The tumor was considered unresectable
and a liver transplantation was proposed; this was accepted by the patient.
Figure 1 CT scan: Bile duct dilatation, stones and a mass filling some right lobe cysts.ADENOCARCINOMA IN CAROLI’S DISEASE 83
Eighteen days after the exploratory laparotomy, total hepatectomy and liver
replacement was performed. No veno-venous by-pass was needed, and biliary
reconstruction was with a Roux-en-Y choledochojejunostomy.
Pathological examination of the liver confirmed cystic dilatation with lithiasis,
cholangitis and adenocarcinoma of the intrahepatic bile ducts (Figures 2 and 3),
reactive inflammation in the hilar lymph nodes was found.
Immunosuppression induction consisted of low-dose cyclosporine, prednisone
and prophylactic OKT3 for 5 days. At present the patient is being treated with
cyclosporine and prednisone.
The patient’s postoperative course was uneventful; a mile rejection episode
responded to steroids. The patient was discharged 26 days after liver transplan-
tation with normal hepatic function. She is now alive and well, and shows no
evidence of tumor recurrence 2 years after transplantation.
DISCUSSION
Various authors provide evidence to support the concept of Caroli’s disease as a
premalignant condition6’8. Fozard reported a case complicated by severe displasia
without malignancy; this situation may be considered the first step in the degener-
ation of Caroli’s disease. Cholangiocarcinoma has been reported in approximately
7% of patients with this disease’6, although Phinney
2 found a 14% incidence of
malignancy.
Figure 2 Liver specimen showing biliary cysts with lithiasis and tumor.84 J. BALSELLS ET AL.
Figure 3 Microphotography: papillary adenocarcinoma of bile ducts.
Most of the cases of adenocarcinoma in Caroli’s disease were diagnosed at
necropsy6’14 or as an incidental finding in the pathologic examination of a specimen
from liver resection4a5. At present, Caroli’s disease is diagnosed with imaging
techniques, but possible complications4, such as degeneration, may be diagnosed
earlier with fine needle aspiration cytology and liver biopsy guided by ultrasound.
The majority of cases of carcinoma associated with Caroli’s disease have been
described as adenocarcinoma or cholangiocarcinoma. The bile duct epithelium is
clearly implicated in the origin of these tumors. However, hepatocellular carci-
noma has also been associated with Caroli’s disease2.
From a therapeutic standpoint, a distinction must be drawn between the limited
and total forms of Caroli’s disease. The localized forms, even those associated with
complications, are curable by surgery, and hepatic resection should be aggressively
performed in these selected patientss’9"’s.
Forms involving both lobes of the liver pose difficult therapeutic problems. The
standard techniques in cases without carcinoma involve T-tube drainage of the
common bile duct or internal drainage by biliodigestive anastomosis9. However,
these procedures often result in incomplete decompression of the biliary tree since
the diseased intrahepatic ducts frequently have stenotic segments that cause bile
stasis, recurrent infection, and intrahepatic stones. Another problem is that
congenital cellular aberrations that resulted in the original cystic malformation may
have a predisposition to undergo neoplastic changes independent of bile stasis.
Supporting this idea is the observation that malignant degeneration often occurs inADENOCARCINOMA IN CAROLI’S DISEASE 85
cystic areas despite apparently adequate drainage by patent surgical biliary-enteric
anastomosis6’7. The interval between the drainage procedure and the subsequent
development of carcinoma is usually less than 10 years, and in Flanigan’s review
averaged 4 years6’7. There appears to be a 50% risk of malignant disease in patients
who have undergone a previous biliodigestive drainage procedure7.
It has been stated that the treatment for Caroli’s disease with carcinoma is liver
resection, when feasible. Usually, the involvement of the tumor in both lobes, or
the widespread alteration of the liver parenchyma produced by the disease,
precludes partial hepatectomy. In these cases liver transplantation is the only
possibility for treatment, when extrahepatic tumor spread has been ruled out by a
pretransplant laparotomy with pathologic examination of the hilar lymph nodes13.
Commonly, liver transplantation for Caroli’s disease is indicated in the diffuse
form of the illness with recurrent cholangitis, and when secondary biliary cirrhosis
complicates the disease. Bearing in mind the relatively high incidence of malignant
degeneration after a bilio-digestive drainage procedure7, liver replacement seems
the best therapeutic option for diffuse, advanced Caroli’s disease.
In early liver transplantation trials, a primary hepatic malignancy that could not
be removed by the conventional technique of subtotal hepatic resection was
thought to be an unequivocal indication for liver replacement. Enthusiasm for this
approach has been dampened in several major centers by the high recurrence rates
(ranging from 50 to 80%) of the original malignancies. Long-term survival rates of
approximately 20-30% have been reported from different centers11’13.
,An important prognostic factor for the proper selection of patients, in order to
reduce the incidence of tumor recurrence after transplantation, is the stage of the
tumor13. The rate of survival in lymph-node positive stages is far lower than in
lymph-node negative stages. The 6-month, 1-year and 2-year actuarial survival data
in the Hannover experience
13 for lymph node-negative hepatocellular carcinoma
patients were 83%, 75% and 75%, whereas in the lymph node-positive cases,
results were 33%, 11% and 11%. In lymph node-negative bile duct carcinomas
results were 100%, 100% and 83%, whereas when lymph node-positive, they were
40%, 13% and 0%.
Thus, according to present knowledge, one may consider the lymph node-
negative tumor stage, with no other signs of extrahepatic tumor growth, to be an
indication for liver grafting. A pretransplant laparotomy would clarify the diagnosis
and investigate lymph node involvement, providing information for the resectabi-
lity decision. This pretransplant exploratory laparotomy may be performed at the
transplant laparotomy with another receptor ready in the case of lymph node
involvement.
It is not known if adenocarcinoma associated with Caroli’s disease has a long-
term prognosis different from other bile duct carcinomas because, to our know-
ledge, this is the first report of liver grafting for a neoplasic complication of this
disease.
References
1. Bloustein, P.A. (1977) Association of carcinoma with congenital cystic conditions of the liver and
bile ducts. Am.J.Gastroenterol., 67, 40-46
2. Caroli, J. and Corcos, V. (1964) La dilatation cong6nitale des voies biliaires intra-h6patiques.
Rev. Med. Chir. Mal. Foie, 39, 1-786 J. BALSELLS ET AL.
3. Caroli, J., Couinaud, D., Saupault, R., Porcher, P. and Et6ve, J. (1958) Une affection nouvelle
sans doute cong6nitale des voies biliaires. La dilatation unilobaire des canaux h6patiques.
Sem.Hop.Paris, 34, 136-143
4. Chen, K.T.K. (1981) Adenocarcinoma of the liver. Association with Congenital Hepatic Fibrosis
and Caroli’s disease. Arch.Pathol.Lab.Med., 1115, 294-295
5. Chevillotte, G., Sastre, B., Sahel, J., Payan, H., Michotey, G. and Sarles, H. (1984) Maladie de
Caroli localise6 et associe6 hun ad6nocarcinome pappillaire mucos6cr6tant. Int6r6t de la r6section
h6patique. Presse Med., 13, 1137-1139
6. Dayton, M.T., Longmire, W.P. and Tompkins, R.K. (1983) Caroli’s Disease: A premalignant
condition? Am.J.Surg.,145, 41-48
7. Flanigan, D.P. (1977) Biliary carcinoma associated with biliary cysts. Cancer, 40, 880-883
8. Fozard, J.B.J., Wyatt, J.I. and Hall, R.I. (1989) Epithelial dysplasia in Caroli’s disease. Gut, 30,
1150-1153
9. Mercadier, M., Chigot, J.P., Clot, J.P., Langlois, P. and Lansiaux, P. (1984) Caroli’s Disease.
World J.Surg., 8, 22-29
10. Nagasue, N. (1984) Successful treatment of Caroli’s disease by hepatic resection. Ann.Surg., 200,
718-723
11. O’Grady, J.G., Poison, R.J., Rolles, K., Calne, R.R. and Williams, R. (1988) Liver transplan-
tation for malignant disease. Ann.Surg., 207, 373-379
12. Phinney, P.R., Austin, G.E. and Kadell, B.M. (1981) Cholangiocarcinoma arising in Caroli’s
disease. Arch.Pathol.Lab.Med., 105, 194-197
13. Ringe, B., Wittekind, C., Bechstein, W.O., Bunzendahl, H. and Pichlmayr, R. (1989) The role of
liver transplantation in hepatobiliary malignancy: A retrospective analysis of 95 patients with
particular regard to tumor stage and recurrence. Ann.Surg., 209, 88-98
14. Rogstad, K., Freeman, J., Moorghen, M. and Record, C.O. (1986) Difficulty in diagnosing
complications of Caroli’s disease. J. Clin. Gastroenterol., 8, 582-585
15. Roudot-Thoraval, F., Zafrani, E.S., Hannoun, S., Fagniez, P.L., M6treau, J.M. and Dhumeaux,
D. (1983) R6section h6patique pour maladie de Caroli limite6au foie gauche. D6couverte fortuite
d’un cholangio-carcinome. Gastroenterol. Clin.Biol., 7,319-320
(Accepted by S. Bengmark 21 January 1993)
INVITED COMMENTARY
Balsells et al. describe the first case of successful liver transplantation for nonresec-
table cholangiocellular carcinoma arising from Caroli’s disease in a 25 year old
patient. Due to chronic inflammation cystic dilation of the intrahepatic bile ducts is
known to predispose to development of adeno- or less frequently hepatocellular
and squamous cell carcinoma. From the literature the authors report an incidence
of 7%. Generally, prognosis of cholangiocellular carcinoma is very unfavourable.
Our own experience with liver transplantation for nonresectable cholangiocellular
carcinoma in 14 patients showed a median survival rate of 4 months. All patients
surviving more than 30 days died from tumor recurrence. This is worse than in
other hepato-biliary malignancies and has to be differentiated sharply from proxi-
mal bile duct carcinoma of the hilar type with a much better prognosis- in our
series 4 patients survived more than 5 years. Therefore, with special regard to the
limited availability of donor organs, the indication for liver transplantation, even in
the case of a lymph node negative stage, has to be discussed critically and we should
perform an extended resection whenever feasible.ADENOCARCINOMA IN CAROLI’S DISEASE 87
We agree with the authors that resection with partial hepatectomy is the
treatment of choice especially for localized symptomatic Caroli disease without
tumor. Even in bilateral disease partial hepatectomy can be discussed because in
some of our patients considerable relief from cholangitis was observed. The typical
indication for liver transplantation should be related to secondary biliary cirrhosis
and impairment of liver function. So far, we have performed liver transplantation
in 3 patients with advanced biliary cirrhosis in one case combined with renal
transplantation for chronic glomerulonephritis. Two patients are alive 1.5 and 4
years after transplanttion. With regard to the risk of carcinoma in Caroli’s disease
and similarly in primary sclerosing cholangitis, there is a dilemma about the
decision to transplant as malignancy usually cannot be diagnosed in an early stage.
Carcinoma has to be suspected in case of sudden clinical deterioration and
increasing jaundice, accompanied by elevation of tumormarkers CEA or CA 19/9
in the serum. However, clear criteria for the optimum time for transplantation
cannot be defined yet. One of our patients who had undergone partial hepatectomy
for Caroli’s disease subsequently developed carcinoma. Due to rapid tumor
progress the patient died before liver transplantation could be performed.
The excellent result of Balsells et al. presenting a patient who is alive for more
than two years after transplantation without evidence of tumor recurrence has led
the authors to suggest that Caroli associated cholangiocellular carcinoma might
have a better prognosis. This hypothesis has to be elucidated in the future.
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